drugset / Trial / NCT01406262

Albiglutide Thorough ECG Study in Healthy Volunteers

NCT01406262

Phase 1 Completed 94 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindBasic science

Summary

This study is designed to investigate the effect of treatment with albiglutide on the cardiac repolarization (corrected QT interval) in healthy male and female subjects. Moxifloxacin, a positive control, or moxifloxacin placebo will be given in order to validate the ability of the study to detect a change in the corrected QT interval.

Timeline

Start
2011-07-06
Primary completion
2011-12-29
Completion
2011-12-29

Drugs

EvaluationDrugModalityDoseRoute
Comparator Moxifloxacin Small molecule 400 mg Oral
Comparator albiglutide Peptide Subcutaneous